You are here

Article Text

Article menu
Download PDFPDF
Archimedes
Question 1: Co-trimoxazole dosing dilemma: what is the right dose?
  1. Alison Boast1,
  2. Joshua Osowicki1,2,
  3. Theresa Cole3,
  4. Nigel Curtis1,2,4,
  5. Amanda Gwee1,2,4
  1. 1 Infectious Diseases Unit, Department of General Medicine, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
  2. 2 Murdoch Childrens Research Institute, Parkville, Victoria, Australia
  3. 3 Department of Allergy and Immunology, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
  4. 4 Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
  1. Correspondence to Dr Amanda Gwee, Department of General Medicine, The Royal Children's Hospital Melbourne, 50 Flemington Rd, Parkville, VIC 3052, Australia; amanda.gwee{at}rch.org.au

https://doi.org/10.1136/archdischild-2015-309100

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Scenario

    While covering the paediatric haematology–oncology ward, you are asked to prescribe co-trimoxazole for prophylaxis against Pneumocystis jirovecii pneumonia (PJP). You refer to your usual drug resources discovering a variety of different dosing options and wonder which regimen you should prescribe.

    Structured clinical question

    In immunocompromised children and adolescents without HIV infection (patient), which co-trimoxazole dosing regimen (intervention) is most effective in preventing PJP and best tolerated (outcome)?

    Search strategy and outcome

    We searched Medline (1946 to current) and Embase (1974 to current) via the OVID interface in July 2015. The following keywords were used: trimethoprim (TMP)–sulfamethoxazole combination, TMP, sulfamethoxazole, drug combinations, pneumocystis infections, pneumocystis, pneumocystis pneumonia, chemoprevention, prophylaxis, chemoprophylaxis, prevention and control, infant, newborn, neonate, babies or baby, toddler, preschooler, child, adolescent, or paediatric. The search was limited to English language studies in humans aged 0–18 years. This identified a total of 972 publications. Articles were included if the specific dosing regimen of TMP–sulfamethoxazole was stated and outcomes were reported separately for patients under 18 years of age. Only studies examining PJP as an outcome were included. Studies of children with HIV infection and those without a robust case definition for PJP were excluded. Eleven articles fulfilled the inclusion criteria (table 1). The references of all articles were reviewed and no additional studies were identified.

    View this table:
    • In this window
    • In a new window
    Table 1

    Summary of evidence

    Commentary

    PJP is an opportunistic fungal infection that occurs in primary or acquired immunodeficiency syndromes. Prior to the widespread use of PJP prophylaxis, 15%–43% of children treated for haematological malignancies were affected.1 ,2 Combination TMP and sulfamethoxazole (co-trimoxazole) is effective in preventing PJP and is now the preferred prophylactic agent.3 ,4 However, there is significant variation in recommended dosing regimens. These range from doses on 1–3 consecutive or non-consecutive days per week, administered in 1–2 doses/day, calculated either by weight (usually 5 mg/kg/day TMP component) or body surface area …

    View Full Text

    Footnotes

    • Contributors AB and JO conducted the search and prepared the table and text. TC, NC and AG were involved in planning the study, interpreting results and editing through multiple revisions. All authors gave final approval for submission of the manuscript in its current form.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles